508:
the 3rd year of follow-up showed that the efficacy of the vaccine was 65.6% in preventing hospitalization in children older than nine years of age, but considerably greater (81.9%) for children who were seropositive (indicating previous dengue infection) at baseline. The vaccination series consists of three injections at 0, 6 and 12 months. The vaccine was approved in Mexico, the
Philippines, and Brazil in December 2015, and in El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand, and Singapore in 2016. Under the brand name Dengvaxia, it is approved for use for those aged nine years of age and older and can prevent all four serotypes.
681:(EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Qdenga, intended for prophylaxis against dengue disease. The applicant for this medicinal product is Takeda GmbH. The active substance of Qdenga is dengue tetravalent vaccine (live, attenuated), a viral vaccine containing live attenuated dengue viruses which replicate locally and elicit humoral and cellular immune responses against the four dengue virus serotypes. Qdenga was approved for medical use in the European Union in December 2022.
754:(DOH). The DOH vaccinated schoolchildren with Sanofi Pasteur's CYD-TDV (Dengvaxia) dengue vaccine. Some of the children who received the vaccine had never been infected by the dengue virus before. The program was stopped when Sanofi Pasteur advised the government that the vaccine could put previously uninfected people at a somewhat higher risk of a severe case of dengue fever. A political controversy erupted over whether the program was run with sufficient care and who should be held responsible for the alleged harm to the vaccinated children.
517:
4110:
4098:
500:
understanding of increased risk of severe dengue in participants who had not been previously exposed. In
November 2017, Sanofi acknowledged that some participants were put at risk of severe dengue if they had no prior exposure to the infection; subsequently the Philippine government suspended the mass immunization program with the backing of the WHO which began a review of the safety data.
1696:
1352:
492:(WHO) recommends that countries should consider vaccination with the dengue vaccine CYD-TDV only if the risk of severe dengue in seronegative individuals can be minimized either through pre-vaccination screening or recent documentation of high seroprevalence rates in the area (at least 80% by age nine years).
555:
Qdenga received approval for use in the
European Union in 2022 for people aged 4 and above, and is also approved in the United Kingdom, Brazil, Argentina, Indonesia, and Thailand. Takeda voluntarily withdrew their application for the vaccination's approval in the United States in July 2023 after
383:
In May 2019, Dengvaxia was approved in the United States as the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages nine through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas. Dengue
507:
was 56.5% in the Asian study and 64.7% in the Latin
American study in patients who received at least one injection of the vaccine. Efficacy varied by serotype. In both trials vaccine reduced by about 80% the number of severe dengue cases. An analysis of both the Latin American and Asian studies at
437:
made using recombinant DNA technology by replacing the PrM (pre-membrane) and E (envelope) structural genes of the yellow fever attenuated 17D strain vaccine with those from the four dengue serotypes. Evidence indicates that CYD-TDV is partially effective in preventing infection, but may lead to a
387:
The safety and effectiveness of the vaccine was determined in three randomized, placebo-controlled studies involving approximately 35,000 individuals in dengue-endemic areas, including Puerto Rico, Latin
America and the Asia Pacific region. The vaccine was determined to be approximately 76 percent
499:
In 2017, the manufacturer recommended that the vaccine only be used in people who have previously had a dengue infection as otherwise there was evidence it may worsen subsequent infections. The initial protocol did not require baseline blood samples prior to vaccination in order to establish an
551:
Data from the phase III trial, which began in
September 2016, show that TAK-003 was efficacious against symptomatic dengue. TAK-003 appears to not lack efficacy in seronegative people or potentially cause them harm, unlike CYD-TDV. The data appear to show only moderate efficacy in other dengue
495:
The WHO updated its recommendations regarding the use of
Dengvaxia in 2018, based on long-term safety data stratified by serostatus on 29 November 2017. Seronegative vaccine recipients have an excess risk of severe dengue compared to unvaccinated seronegative individuals. For every 13
692:
633:(WRAIR). A synergistic formulation with another live attenuated candidate vaccine (prime-boost strategy) is also being evaluated in a phase II study. In prime-boosting, one type of vaccine is followed by a boost with another type in an attempt to improve immunogenicity.
1857:
Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. (October 2014). "Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial".
449:
was one of the first researchers to identify the ADE phenomenon. Dr. Halstead and his colleague Dr. Phillip
Russell proposed that the vaccine only be used after antibody testing, to check for prior dengue exposure and avoid vaccination of sero-negative individuals.
345:. The value of Dengvaxia is limited by the fact that it may increase the risk of severe dengue in those who have not previously been infected. In 2017, more than 733,000 children and more than 50,000 adult volunteers were vaccinated with Dengvaxia regardless of
464:
Dengvaxia became commercially available in 2016 in 11 countries: Mexico, the
Philippines, Indonesia, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Thailand, and Singapore. In 2019 it was approved for medical use in the United States. It is on the
438:
higher risk of severe disease in those who have not been previously infected and then do go on to contract the disease. It is not clear why the vaccinated seronegative population have more serious adverse outcomes. A plausible hypothesis is the phenomenon of
429:
The vaccine has been approved in 19 countries and the
European Union, but it is not approved in the US for use in individuals not previously infected by any dengue virus serotype or for whom this information is unknown.
697:
543:
in Bangkok and now funded by Inviragen (DENVax) and (TAK-003). Phase I and II trials were conducted in the United States, Colombia, Puerto Rico, Singapore and Thailand. The 18-month data published in the journal
1372:
472:
In 2017, the manufacturer recommended that the vaccine only be used in people who have previously had a dengue infection, as outcomes may be worsened in those who have not been previously infected due to
496:
hospitalizations prevented in seropositive vaccinees, there would be 1 excess hospitalization in seronegative vaccinees per 1,000 vaccinees. WHO recommends serological testing for past dengue infection
1337:
617:
A company in Vietnam (Vabiotech) is conducting safety tests and developing a clinical trial plan. All four companies are involved in studies of a TetraVax-DV vaccine in conjunction with the US NIH.
2606:
2022:
402:
approved Qdenga for use in individuals six years to 45 years of age and become the first authority in the world to approve Qdenga. Qdenga was approved in the European Union in December 2022.
1282:
580:
has conducted phase I and phase II studies in over 1,000 participants in the US. It has also conducted human challenge studies while having conducted NHP model studies successfully.
199:
4140:
2554:
2769:
2693:"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naĂŻve adults"
2659:
388:
effective in preventing symptomatic, laboratory-confirmed dengue disease in individuals 9 through 16 years of age who previously had laboratory-confirmed dengue disease.
1832:
1543:
341:
Dengvaxia is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected due to phenomenon known as
573:, that were tested separately for safety and immunogenicity. The vaccine passed phase I trials and phase II studies in the US, Thailand, Bangladesh, India, and Brazil.
418:
tetravalent vaccine that is administered as three separate injections, with the initial dose followed by two additional shots given six and twelve months later. The US
2449:"Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?"
2820:
797:
461:. Safety of use during pregnancy is unclear. Dengvaxia is a weakened but live vaccine and works by triggering an immune response against four types of dengue virus.
2321:
2152:
721:
In July 2023, Takeda withdrew its application for Qdenga before the FDA, citing the FDA's requirement for additional data not captured in the phase III studies.
503:
Phase III trials in Latin America and Asia involved over 31,000 children between the ages of two and 14 years. In the first reports from the trials, vaccine
154:
1325:
823:
548:, indicate that TAK-003 produced sustained antibody responses against all four virus strains, regardless of previous dengue exposure and dosing schedule.
685:
2026:
2951:
2376:
1254:
747:
2351:
4001:
1569:
1774:
849:
2282:
3149:
674:
2306:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
2224:
1950:
3038:
2580:
92:
2897:
3189:
3184:
1373:"Takeda's Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure"
1096:(24 November 2023). "Meeting of the Strategic Advisory Group of Experts on Immunization, September 2023: conclusions and recommendations".
1197:
Redoni M, Yacoub S, Rivino L, Giacobbe DR, Luzzati R, Di Bella S (July 2020). "Dengue: Status of current and under-development vaccines".
946:
2932:
326:
in humans. Development of dengue vaccines began in the 1920s, but was hindered by the need to create immunity against all four dengue
1681:
399:
625:
TDENV PIV (tetravalent dengue virus purified inactivated vaccine) is undergoing phase I trials as part of a collaboration between
3581:
1655:
3370:
2666:
2632:
906:
3199:
1395:
630:
453:
Common side effects include headache, pain at the site of injection, and general muscle pains. Severe side effects may include
4052:
3980:
466:
1125:
Freedman DO (November 2023). "A new dengue vaccine (TAK-003) now WHO recommended in endemic areas; what about travellers?".
3586:
2740:
2246:
556:
the FDA sought further data from the firm, which the company stated could not be provided during the current review cycle.
17:
3618:
3375:
3301:
3154:
2981:
2555:"Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections"
1980:
Hadinegoro SR, Arredondo-GarcĂa JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. (September 2015).
876:"Qdenga powder and solvent for solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)"
4028:
3340:
2973:
751:
660:
attempted to develop a monovalent DNA plasmid vaccine, but early results showed it to be only moderately immunogenic.
3440:
1493:
715:
426:
designation and a tropical disease priority review voucher. The approval of Dengvaxia was granted to Sanofi Pasteur.
129:
4069:
4007:
2982:
772:"Dengvaxia dengue tetravalent vaccine (live, attenuated), powder and diluent for suspension for injection (275964)"
3628:
3596:
3591:
3425:
2050:"Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever"
184:
110:
2400:"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model"
3686:
3296:
474:
439:
342:
648:
cells. As of 2019, it had completed phase I stage and found V180 formulations to be generally well tolerated.
3484:
3194:
2871:
2846:
1630:
733:
for the recommended three doses as of 2016. Indonesia was the first country to approve Qdenga, in late 2022.
707:
657:
577:
525:
2174:
Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, et al. (November 2019).
1675:
1331:
419:
2795:
2293:
4088:
3606:
3048:
3031:
1283:"Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries"
3656:
2745:
2287:
2251:
1805:
1741:
1713:
1219:
1165:
1093:
978:
940:
678:
489:
481:
where more than 733,000 children and more than 50,000 adult volunteers were vaccinated regardless of
392:
3611:
3576:
3571:
3566:
2945:
1901:
Villar L, Dayan GH, Arredondo-GarcĂa JL, Rivera DM, Cunha R, Deseda C, et al. (January 2015).
1599:
588:
2926:
2398:
Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, et al. (March 2016).
384:
is endemic in the US territories of American Samoa, Guam, Puerto Rico, and the US Virgin Islands.
369:
4057:
3990:
3971:
3767:
3739:
3701:
3696:
3676:
3204:
140:
74:
1958:
583:
NIH has licensed their technology for further development and commercial scale manufacturing to
4038:
3967:
2966:
1517:
147:
2691:
Manoff SB, Sausser M, Falk Russell A, Martin J, Radley D, Hyatt D, et al. (3 June 2019).
2352:"UPDATED: Takeda yanks FDA filing for dengue vaccine, citing data disagreement with regulator"
1248:
1246:
935:
4130:
4033:
3867:
3862:
3318:
3264:
3174:
478:
350:
267:
1544:"Dengue Vaccine Maker Struggles to Find a Diagnostic That Will Make Its Product Safe to Use"
3916:
3857:
3648:
3291:
3169:
3120:
3087:
3021:
2941:
1951:"The Lancet: World's Most Advanced Dengue Vaccine Candidate Shows Promise in Phase 3 Trial"
1800:
1243:
1013:
973:
102:
8:
3839:
3805:
3691:
3514:
3457:
3452:
3403:
3234:
3102:
3074:
3026:
1669:
395:
accepted the filing package for TAK-003 (Qdenga) intended for markets outside of the EU.
361:
258:
3509:
3254:
330:. As of 2023, there are two commercially available vaccines, sold under the brand names
3872:
3706:
3447:
3413:
3398:
3274:
3259:
3244:
3164:
3082:
2717:
2692:
2531:
2504:
2473:
2448:
2429:
2205:
2128:
2103:
2074:
2049:
1932:
1883:
1485:
1446:
1421:
1232:
1070:
1045:
603:
592:
540:
415:
357:
62:
1871:
4135:
3995:
3962:
3795:
3636:
3526:
3420:
3281:
3106:
3069:
2959:
2722:
2536:
2478:
2433:
2421:
2209:
2197:
2133:
2079:
2003:
1924:
1875:
1499:
1489:
1451:
1236:
1224:
1142:
1075:
458:
221:
3941:
2636:
1887:
1326:"First FDA-approved vaccine for the prevention of dengue disease in endemic regions"
702:(ANMAT) gave the green light to the use of the tetravalent vaccine TAK-003 known as
569:
TV-003/005 is a tetravalent admixture of monovalent vaccines, that was developed by
3921:
3906:
3762:
3623:
3536:
2712:
2704:
2526:
2516:
2468:
2460:
2411:
2187:
2123:
2115:
2069:
2061:
1993:
1936:
1914:
1867:
1749:
1721:
1481:
1441:
1433:
1214:
1206:
1177:
1134:
1105:
1065:
1057:
504:
167:
3462:
2821:"Takeda UK Ltd. announces MHRA approval for dengue virus vaccine candidate Qdenga"
2708:
2464:
2119:
2065:
798:"Prescription medicines: registration of new chemical entities in Australia, 2017"
4102:
3926:
3724:
3531:
3489:
3380:
3360:
3330:
3313:
3239:
3229:
3159:
3098:
3094:
3043:
2898:"As approvals roll in, Takeda details pricing strategy for dengue vaccine launch"
2416:
2399:
1982:"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease"
1061:
1046:"Dengue vaccines: recent developments, ongoing challenges and current candidates"
875:
626:
529:
434:
423:
850:"Vacina contra a dengue: aplicação começa nesta semana em clĂnicas particulares"
4114:
4063:
3790:
3641:
3521:
3347:
3286:
771:
641:
611:
584:
446:
411:
33:
2581:"MVC Obtains US NIH's Authorization to Develop Dengue Vaccine in 17 Countries"
2176:"Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents"
2023:"Sanofi gets first approval for long-anticipated vaccine against dengue fever"
852:[Dengue vaccine: administration starts this week in private clinics].
4124:
3946:
3931:
3901:
3896:
3751:
3504:
3499:
3408:
3053:
1746:
World Health Organization model list of essential medicines: 22nd list (2021)
1700:
1437:
1356:
3308:
2104:"The dengue vaccine pipeline: Implications for the future of dengue control"
4023:
3666:
3561:
3494:
3435:
3115:
3006:
2986:
2726:
2540:
2521:
2482:
2425:
2377:"NIH-Developed Candidate Dengue Vaccine Shows Promise in Early-Stage Trial"
2201:
2153:"With interim phase 2 data, Takeda's dengue vaccine casts shadow on Sanofi"
2137:
2083:
2007:
1928:
1879:
1718:
World Health Organization model list of essential medicines: 21st list 2019
1503:
1455:
1228:
1146:
1079:
536:
532:
323:
162:
50:
2192:
2175:
1998:
1981:
1919:
1902:
1518:"Caution on new dengue vaccine: In some countries, harm outweighs benefit"
1138:
3810:
3800:
3661:
3467:
3355:
3323:
3249:
3111:
3002:
2994:
1168:(September 2018). "Dengue vaccine: WHO position paper – September 2018".
596:
454:
365:
2379:. National Institute of Allergy and Infectious Diseases. 23 January 2013
1979:
1754:
1726:
1182:
1110:
516:
287:
3936:
3911:
3601:
3551:
1903:"Efficacy of a tetravalent dengue vaccine in children in Latin America"
645:
545:
482:
443:
346:
298:
57:
2741:"New vaccine to protect people in the EU and worldwide against dengue"
2247:"New vaccine to protect people in the EU and worldwide against dengue"
1396:"Takeda's dengue fever vaccine picks up first global nod in Indonesia"
3985:
3556:
3429:
2998:
1285:(Press release). Takeda Pharmaceutical Company Limited. 25 March 2021
1210:
711:
96:
1775:"Sanofi restricts dengue vaccine but downplays antibody enhancement"
1570:"Sanofi restricts dengue vaccine but downplays antibody enhancement"
520:
A carton of Qdenga vials awaiting administration in BrasĂlia, Brazil
3827:
3820:
3815:
3785:
3541:
3477:
3472:
710:, making it the only vaccine approved to date. to combat dengue in
327:
278:
124:
3546:
2990:
1900:
1699:
This article incorporates text from this source, which is in the
1604:
1355:
This article incorporates text from this source, which is in the
824:"Prescription medicines and biologicals: TGA annual summary 2017"
319:
40:
2397:
2048:
Osorio JE, Huang CY, Kinney RM, Stinchcomb DT (September 2011).
1631:"World's first dengue fever vaccine launched in the Philippines"
1472:
Yauch LE, Shresta S (2014). "Dengue virus vaccine development".
535:
attenuated vaccine with DENV1, DENV3, and DENV4 components on a
524:
TAK-003 or DENVax, sold under the brand name Qdenga and made by
380:
In December 2018, Dengvaxia was approved in the European Union.
3849:
3834:
3125:
2690:
2607:"Panacea Biotec completes Phase I/II study of DengiAlI vaccine"
2173:
703:
2322:"Takeda withdraws US application for dengue vaccine candidate"
2277:
2275:
2273:
2271:
1422:"Latest developments and future directions in dengue vaccines"
3844:
3729:
3335:
3269:
2505:"Dengue Fever: Causes, Complications, and Vaccine Strategies"
2102:
Schwartz LM, Halloran ME, Durbin AP, Longini IM (June 2015).
2101:
1255:"DOJ orders NBI to investigate P3.5-B dengue vaccine scandal"
693:
National Administration of Drugs, Food and Medical Technology
570:
4109:
2770:"Takeda's Dengue Vaccine Approved for Use in European Union"
1856:
356:
There are other vaccine candidates in development including
3144:
2268:
2047:
1833:"Did Sanofi, WHO ignore warning signals on dengue vaccine?"
353:. Qdenga is designated for people not previously infected.
1196:
1740:
1712:
1164:
1092:
607:
410:
CYD-TDV, sold under the brand name Dengvaxia and made by
4141:
World Health Organization essential medicines (vaccines)
1730:. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
467:
World Health Organization's List of Essential Medicines
644:
is studying recombinant subunit vaccines expressed in
4086:
2225:"Takeda's dengue data spell more bad news for Sanofi"
1043:
901:
899:
897:
1830:
1419:
602:
In Brazil, phase III studies are being conducted by
2345:
2343:
1826:
1824:
686:
Medicines and Healthcare products Regulatory Agency
1600:"Sanofi's dengue vaccine approved in 11 countries"
894:
748:2017 dengue vaccine controversy in the Philippines
614:has conducted phase II clinical studies in India.
4002:Cedillo v. Secretary of Health and Human Services
1044:McArthur MA, Sztein MB, Edelman R (August 2013).
1014:"Dengue Vaccine Live Monograph for Professionals"
907:"Dengvaxia- dengue tetravalent vaccine, live kit"
4122:
2889:
2633:"Vaccine Development. Dengue Vaccine Initiative"
2340:
2097:
2095:
2093:
1821:
930:
928:
684:In February 2023, Qdenga was approved by the UK
539:type 2 (DENV2) backbone originally developed at
2502:
2316:
2314:
2312:
1943:
1831:Steenhuysen J, Hirschler B (12 December 2017).
266:
2927:"Dengue Vaccine Vaccine Information Statement"
2660:"Current Status of Dengue Vaccine Development"
1593:
1591:
1413:
675:Committee for Medicinal Products for Human Use
2967:
2090:
1656:"Dengue Fever Vaccine Available in Indonesia"
1039:
1037:
1035:
968:
966:
964:
925:
688:(MHRA) for people aged four years and older.
2309:
2020:
1624:
1622:
1510:
1471:
1467:
1465:
422:(FDA) granted the application for Dengvaxia
128:
1650:
1648:
1588:
1420:Thisyakorn U, Thisyakorn C (January 2014).
1320:
245:In general: â„ž (Prescription only)
2974:
2960:
2933:Centers for Disease Control and Prevention
1769:
1767:
1765:
1318:
1316:
1314:
1312:
1310:
1308:
1306:
1304:
1302:
1300:
1160:
1158:
1156:
1032:
1008:
1006:
1004:
1002:
1000:
998:
961:
750:involved a vaccination program run by the
2944:at the U.S. National Library of Medicine
2716:
2530:
2520:
2472:
2446:
2415:
2222:
2191:
2127:
2073:
1997:
1918:
1753:
1725:
1619:
1462:
1445:
1367:
1365:
1277:
1275:
1220:1983/6d38d9b6-8e1b-4a84-85e3-edab4fc41957
1218:
1181:
1109:
1069:
1645:
1124:
515:
457:. Use is not recommended in people with
2872:"Dengue vaccine available in Argentina"
2847:"Dengue vaccine available in Argentina"
2697:Human Vaccines & Immunotherapeutics
2657:
2498:
2496:
2494:
2492:
1762:
1734:
1706:
1597:
1375:(Press release). Takeda. 22 August 2022
1297:
1153:
1086:
995:
706:, developed by the Japanese laboratory
286:
14:
4123:
2895:
1393:
1362:
1272:
828:Therapeutic Goods Administration (TGA)
802:Therapeutic Goods Administration (TGA)
776:Therapeutic Goods Administration (TGA)
663:
631:Walter Reed Army Institute of Research
405:
237:
215:
2955:
2349:
1748:. Geneva: World Health Organization.
1720:. Geneva: World Health Organization.
1252:
228:
119:
101:
2800:Union Register of medicinal products
2489:
1684:from the original on 6 December 2019
1628:
1340:from the original on 6 December 2019
949:from the original on 6 December 2019
166:
2864:
2180:The New England Journal of Medicine
2150:
1986:The New England Journal of Medicine
1907:The New England Journal of Medicine
1801:"Vaccines and immunization: Dengue"
729:In Indonesia, Dengvaxia cost about
511:
24:
4029:Eradication of infectious diseases
3786:Androvax (androstenedione albumin)
2839:
1486:10.1016/B978-0-12-800098-4.00007-6
25:
4152:
3619:Respiratory syncytial virus (RSV)
2919:
2292:. 14 October 2022. Archived from
559:
193:
4108:
4096:
4008:Alternative vaccination schedule
2983:Artificial induction of immunity
2827:(Press release). 6 February 2023
2776:(Press release). 8 December 2022
2750:(Press release). 14 October 2022
2256:(Press release). 14 October 2022
2021:Palmer, Eric (9 December 2015).
1694:
1426:Therapeutic Advances in Vaccines
1350:
752:Philippines Department of Health
736:
2813:
2788:
2762:
2733:
2684:
2651:
2625:
2599:
2573:
2547:
2440:
2391:
2369:
2239:
2223:Armstrong M (7 November 2019).
2216:
2167:
2144:
2041:
2014:
1973:
1894:
1850:
1793:
1662:
1562:
1536:
1387:
1190:
1118:
668:
651:
3840:Ovandrotone albumin (Fecundin)
2509:Journal of Immunology Research
2503:Khetarpal N, Khanna I (2016).
2404:Science Translational Medicine
2025:. FiercePharma. Archived from
1957:. 10 July 2014. Archived from
868:
842:
816:
790:
764:
741:
479:controversy in the Philippines
475:antibody-dependent enhancement
440:antibody-dependent enhancement
343:antibody-dependent enhancement
206:
13:
1:
3376:Group B streptococcal disease
3195:Vaccines for Children Program
2709:10.1080/21645515.2018.1546523
2465:10.1586/14760584.2016.1115727
2283:"Qdenga: Pending EC decision"
2120:10.1016/j.vaccine.2015.05.010
2066:10.1016/j.vaccine.2011.07.020
1872:10.1016/s0140-6736(14)61060-6
1336:(Press release). 1 May 2019.
1170:Weekly Epidemiological Record
1098:Weekly Epidemiological Record
856:(in Portuguese). 26 June 2023
757:
708:Takeda Pharmaceutical Company
658:Naval Medical Research Center
578:National Institutes of Health
564:
2796:"Qdenga Product information"
2417:10.1126/scitranslmed.aaf1517
1676:Food and Drug Administration
1598:Vidalon D (4 October 2016).
1332:Food and Drug Administration
1062:10.1586/14760584.2013.815412
724:
620:
420:Food and Drug Administration
27:Vaccine against dengue fever
7:
1680:. 21 May 2019. STN 125682.
1394:Becker Z (22 August 2022).
1253:Lopez V (4 December 2017).
1199:Reviews in Medical Virology
10:
4157:
2896:Becker Z (21 March 2023).
1758:. WHO/MHP/HPS/EML/2021.02.
1474:Advances in Virus Research
714:. It has been used in the
546:Lancet Infectious Diseases
375:
4047:
4016:
3955:
3887:
3778:
3750:
3717:
3391:
3222:
3215:
3134:
3062:
3014:
2746:European Medicines Agency
2658:Roehrig JT (April 2013).
2453:Expert Review of Vaccines
2288:European Medicines Agency
2252:European Medicines Agency
2151:Liu A (7 November 2017).
1955:Science Newsline medicine
1806:World Health Organization
1742:World Health Organization
1714:World Health Organization
1166:World Health Organization
1094:World Health Organization
1050:Expert Review of Vaccines
979:European Medicines Agency
941:European Medicines Agency
679:European Medicines Agency
490:World Health Organization
393:European Medicines Agency
297:
277:
257:
252:
233: Rx-only (Dengvaxia)
183:
178:
153:
139:
109:
91:
83:
73:
68:
56:
46:
39:
3371:Clostridioides difficile
2946:Medical Subject Headings
2350:Angus L (11 July 2023).
1438:10.1177/2051013613507862
673:On 13 October 2022, the
589:Serum Institute of India
3629:Tick-borne encephalitis
1629:East S (6 April 2016).
636:
4039:List of vaccine topics
3039:Mathematical modelling
606:in-collaboration with
552:serotypes than DENV2.
521:
4034:Vaccinate Your Family
3485:Japanese encephalitis
2447:Whitehead SS (2016).
2193:10.1056/NEJMoa1903869
1999:10.1056/NEJMoa1506223
1920:10.1056/nejmoa1411037
519:
3917:John Franklin Enders
2522:10.1155/2016/6803098
716:2024 dengue epidemic
459:poor immune function
398:In August 2022, the
18:Dengue fever vaccine
3103:Virus-like particle
3027:Vaccine ingredients
2672:on 11 December 2015
2613:. 24 September 2020
1866:(9951): 1358–1365.
1548:Scientific American
1139:10.1093/jtm/taad132
945:. 23 October 2019.
691:In April 2023, the
664:Society and culture
406:CYD-TDV (Dengvaxia)
391:In March 2021, the
224:(Prescription only)
202:(Prescription only)
41:Vaccine description
36:
4074:Never to phase III
3873:Hexavalent vaccine
3687:Epstein–Barr virus
3582:Oxford–AstraZeneca
3275:NmVac4-A/C/Y/W-135
2561:. 12 December 2018
2296:on 14 October 2022
1658:. 17 October 2016.
1524:. 1 September 2016
983:. 16 December 2022
604:Instituto Butantan
593:Instituto Butantan
541:Mahidol University
522:
32:
4084:
4083:
3996:Vaccines and SIDS
3883:
3882:
3657:Hepatitis A and B
3633:Varicella zoster
3095:Subunit/component
2639:on 21 August 2019
2587:. 9 December 2016
2186:(21): 2009–2019.
2114:(29): 3293–3298.
2060:(42): 7251–7260.
1992:(13): 1195–1206.
1576:. 1 December 2017
313:
312:
241:
232:
219:
210:
197:
122:
79:Dengvaxia, Qdenga
16:(Redirected from
4148:
4113:
4112:
4101:
4100:
4099:
4092:
3975:MMR autism fraud
3922:Maurice Hilleman
3907:Hilary Koprowski
3220:
3219:
2976:
2969:
2962:
2953:
2952:
2938:
2937:. December 2021.
2913:
2912:
2910:
2908:
2893:
2887:
2886:
2884:
2882:
2868:
2862:
2861:
2859:
2857:
2843:
2837:
2836:
2834:
2832:
2817:
2811:
2810:
2808:
2806:
2792:
2786:
2785:
2783:
2781:
2766:
2760:
2759:
2757:
2755:
2737:
2731:
2730:
2720:
2703:(9): 2195–2204.
2688:
2682:
2681:
2679:
2677:
2671:
2665:. Archived from
2664:
2655:
2649:
2648:
2646:
2644:
2635:. Archived from
2629:
2623:
2622:
2620:
2618:
2603:
2597:
2596:
2594:
2592:
2577:
2571:
2570:
2568:
2566:
2551:
2545:
2544:
2534:
2524:
2500:
2487:
2486:
2476:
2444:
2438:
2437:
2419:
2410:(330): 330ra36.
2395:
2389:
2388:
2386:
2384:
2373:
2367:
2366:
2364:
2362:
2347:
2338:
2337:
2335:
2333:
2318:
2307:
2305:
2303:
2301:
2279:
2266:
2265:
2263:
2261:
2243:
2237:
2236:
2234:
2232:
2220:
2214:
2213:
2195:
2171:
2165:
2164:
2162:
2160:
2148:
2142:
2141:
2131:
2099:
2088:
2087:
2077:
2045:
2039:
2038:
2036:
2034:
2029:on 16 March 2016
2018:
2012:
2011:
2001:
1977:
1971:
1970:
1968:
1966:
1947:
1941:
1940:
1922:
1898:
1892:
1891:
1854:
1848:
1847:
1845:
1843:
1828:
1819:
1818:
1816:
1814:
1797:
1791:
1790:
1788:
1786:
1771:
1760:
1759:
1757:
1738:
1732:
1731:
1729:
1710:
1704:
1698:
1697:
1693:
1691:
1689:
1666:
1660:
1659:
1652:
1643:
1642:
1640:
1638:
1626:
1617:
1616:
1614:
1612:
1595:
1586:
1585:
1583:
1581:
1566:
1560:
1559:
1557:
1555:
1540:
1534:
1533:
1531:
1529:
1514:
1508:
1507:
1469:
1460:
1459:
1449:
1417:
1411:
1410:
1408:
1406:
1391:
1385:
1384:
1382:
1380:
1369:
1360:
1354:
1353:
1349:
1347:
1345:
1322:
1295:
1294:
1292:
1290:
1279:
1270:
1269:
1267:
1265:
1250:
1241:
1240:
1222:
1211:10.1002/rmv.2101
1194:
1188:
1187:
1185:
1162:
1151:
1150:
1122:
1116:
1115:
1113:
1090:
1084:
1083:
1073:
1041:
1030:
1029:
1027:
1025:
1020:. 23 August 2023
1010:
993:
992:
990:
988:
970:
959:
958:
956:
954:
936:"Dengvaxia EPAR"
932:
923:
922:
920:
918:
903:
892:
891:
889:
887:
872:
866:
865:
863:
861:
846:
840:
839:
837:
835:
820:
814:
813:
811:
809:
794:
788:
787:
785:
783:
768:
732:
701:
512:TAK-003 (Qdenga)
477:. This led to a
442:(ADE). American
435:chimeric vaccine
370:subunit vaccines
322:used to prevent
290:
270:
239:
236:
230:
227:
217:
214:
208:
205:
195:
192:
170:
132:
121:
118:
105:
37:
35:
31:
21:
4156:
4155:
4151:
4150:
4149:
4147:
4146:
4145:
4121:
4120:
4119:
4107:
4097:
4095:
4087:
4085:
4080:
4079:
4064:Clinical trials
4043:
4012:
3951:
3927:Stanley Plotkin
3889:
3879:
3791:Cancer vaccines
3774:
3768:Schistosomiasis
3746:
3740:Trypanosomiasis
3713:
3677:Cytomegalovirus
3587:Pfizer–BioNTech
3387:
3211:
3160:Vaccine wastage
3130:
3058:
3010:
2980:
2942:Dengue Vaccines
2925:
2922:
2917:
2916:
2906:
2904:
2894:
2890:
2880:
2878:
2870:
2869:
2865:
2855:
2853:
2845:
2844:
2840:
2830:
2828:
2819:
2818:
2814:
2804:
2802:
2794:
2793:
2789:
2779:
2777:
2768:
2767:
2763:
2753:
2751:
2739:
2738:
2734:
2689:
2685:
2675:
2673:
2669:
2662:
2656:
2652:
2642:
2640:
2631:
2630:
2626:
2616:
2614:
2605:
2604:
2600:
2590:
2588:
2579:
2578:
2574:
2564:
2562:
2553:
2552:
2548:
2501:
2490:
2445:
2441:
2396:
2392:
2382:
2380:
2375:
2374:
2370:
2360:
2358:
2348:
2341:
2331:
2329:
2320:
2319:
2310:
2299:
2297:
2281:
2280:
2269:
2259:
2257:
2245:
2244:
2240:
2230:
2228:
2221:
2217:
2172:
2168:
2158:
2156:
2149:
2145:
2100:
2091:
2046:
2042:
2032:
2030:
2019:
2015:
1978:
1974:
1964:
1962:
1961:on 15 July 2014
1949:
1948:
1944:
1899:
1895:
1855:
1851:
1841:
1839:
1829:
1822:
1812:
1810:
1799:
1798:
1794:
1784:
1782:
1781:. December 2017
1773:
1772:
1763:
1739:
1735:
1711:
1707:
1695:
1687:
1685:
1668:
1667:
1663:
1654:
1653:
1646:
1636:
1634:
1627:
1620:
1610:
1608:
1596:
1589:
1579:
1577:
1568:
1567:
1563:
1553:
1551:
1542:
1541:
1537:
1527:
1525:
1516:
1515:
1511:
1496:
1470:
1463:
1418:
1414:
1404:
1402:
1392:
1388:
1378:
1376:
1371:
1370:
1363:
1351:
1343:
1341:
1324:
1323:
1298:
1288:
1286:
1281:
1280:
1273:
1263:
1261:
1251:
1244:
1195:
1191:
1163:
1154:
1123:
1119:
1104:(47): 599–620.
1091:
1087:
1042:
1033:
1023:
1021:
1012:
1011:
996:
986:
984:
972:
971:
962:
952:
950:
934:
933:
926:
916:
914:
913:. 9 August 2019
905:
904:
895:
885:
883:
882:. 22 March 2023
874:
873:
869:
859:
857:
848:
847:
843:
833:
831:
822:
821:
817:
807:
805:
796:
795:
791:
781:
779:
770:
769:
765:
760:
744:
739:
730:
727:
695:
671:
666:
654:
639:
627:GlaxoSmithKline
623:
599:, and Medigen.
567:
562:
514:
433:Dengvaxia is a
424:priority review
408:
378:
358:live attenuated
349:, which led to
309:
293:
273:
248:
174:
142:
135:
28:
23:
22:
15:
12:
11:
5:
4154:
4144:
4143:
4138:
4133:
4118:
4117:
4105:
4082:
4081:
4078:
4077:
4076:
4075:
4072:
4061:
4055:
4049:
4048:
4045:
4044:
4042:
4041:
4036:
4031:
4026:
4020:
4018:
4014:
4013:
4011:
4010:
4005:
3998:
3993:
3988:
3983:
3978:
3965:
3959:
3957:
3953:
3952:
3950:
3949:
3944:
3942:Katalin KarikĂł
3939:
3934:
3929:
3924:
3919:
3914:
3909:
3904:
3899:
3893:
3891:
3885:
3884:
3881:
3880:
3878:
3877:
3876:
3875:
3870:
3865:
3860:
3852:
3847:
3842:
3837:
3832:
3831:
3830:
3825:
3824:
3823:
3818:
3808:
3803:
3798:
3788:
3782:
3780:
3776:
3775:
3773:
3772:
3771:
3770:
3765:
3756:
3754:
3748:
3747:
3745:
3744:
3743:
3742:
3734:
3733:
3732:
3721:
3719:
3715:
3714:
3712:
3711:
3710:
3709:
3704:
3699:
3697:Herpes simplex
3694:
3689:
3684:
3679:
3671:
3670:
3669:
3664:
3659:
3651:
3646:
3645:
3644:
3639:
3631:
3626:
3621:
3616:
3615:
3614:
3609:
3604:
3599:
3597:Sinopharm BIBP
3594:
3589:
3584:
3579:
3574:
3569:
3564:
3559:
3554:
3549:
3547:Bharat Biotech
3544:
3534:
3529:
3524:
3519:
3518:
3517:
3512:
3502:
3497:
3492:
3487:
3482:
3481:
3480:
3475:
3465:
3460:
3455:
3450:
3445:
3444:
3443:
3438:
3433:
3418:
3417:
3416:
3406:
3401:
3395:
3393:
3389:
3388:
3386:
3385:
3384:
3383:
3378:
3373:
3365:
3364:
3363:
3358:
3350:
3345:
3344:
3343:
3338:
3328:
3327:
3326:
3316:
3311:
3306:
3305:
3304:
3299:
3289:
3284:
3279:
3278:
3277:
3272:
3262:
3257:
3252:
3247:
3242:
3237:
3232:
3226:
3224:
3217:
3213:
3212:
3210:
3209:
3208:
3207:
3202:
3197:
3192:
3187:
3179:
3178:
3177:
3175:Vaccine injury
3172:
3167:
3162:
3157:
3152:
3147:
3138:
3136:
3135:Administration
3132:
3131:
3129:
3128:
3123:
3118:
3109:
3092:
3091:
3090:
3085:
3077:
3072:
3066:
3064:
3060:
3059:
3057:
3056:
3051:
3046:
3041:
3036:
3035:
3034:
3024:
3018:
3016:
3012:
3011:
2979:
2978:
2971:
2964:
2956:
2950:
2949:
2939:
2921:
2920:External links
2918:
2915:
2914:
2888:
2863:
2838:
2812:
2787:
2761:
2732:
2683:
2650:
2624:
2598:
2572:
2546:
2488:
2459:(4): 509–517.
2439:
2390:
2368:
2339:
2328:. 11 July 2023
2308:
2267:
2238:
2227:. Evaluate Ltd
2215:
2166:
2143:
2089:
2040:
2013:
1972:
1942:
1913:(2): 113–123.
1893:
1849:
1820:
1792:
1761:
1733:
1705:
1661:
1644:
1618:
1587:
1561:
1550:. 17 June 2018
1535:
1509:
1494:
1461:
1412:
1386:
1361:
1296:
1271:
1242:
1189:
1176:(36): 457–76.
1152:
1117:
1085:
1056:(8): 933–953.
1031:
994:
960:
924:
893:
867:
841:
830:. 21 June 2022
815:
804:. 21 June 2022
789:
762:
761:
759:
756:
743:
740:
738:
735:
726:
723:
677:(CHMP) of the
670:
667:
665:
662:
653:
650:
638:
635:
629:(GSK) and the
622:
619:
612:Panacea Biotec
585:Panacea Biotec
566:
563:
561:
560:In development
558:
513:
510:
447:Scott Halstead
412:Sanofi Pasteur
407:
404:
400:Indonesian FDA
377:
374:
316:Dengue vaccine
311:
310:
308:
307:
303:
301:
295:
294:
292:
291:
283:
281:
275:
274:
272:
271:
263:
261:
255:
254:
250:
249:
247:
246:
243:
234:
225:
212:
211: Approved
203:
189:
187:
181:
180:
176:
175:
173:
172:
159:
157:
151:
150:
145:
143:administration
137:
136:
134:
133:
115:
113:
107:
106:
99:
89:
88:
85:
81:
80:
77:
71:
70:
66:
65:
60:
54:
53:
48:
44:
43:
34:Dengue vaccine
26:
9:
6:
4:
3:
2:
4153:
4142:
4139:
4137:
4134:
4132:
4129:
4128:
4126:
4116:
4111:
4106:
4104:
4094:
4093:
4090:
4073:
4071:
4068:
4067:
4065:
4062:
4059:
4056:
4054:
4051:
4050:
4046:
4040:
4037:
4035:
4032:
4030:
4027:
4025:
4022:
4021:
4019:
4015:
4009:
4006:
4004:
4003:
3999:
3997:
3994:
3992:
3989:
3987:
3984:
3982:
3979:
3976:
3974:
3969:
3966:
3964:
3961:
3960:
3958:
3954:
3948:
3947:Drew Weissman
3945:
3943:
3940:
3938:
3935:
3933:
3932:H. Fred Clark
3930:
3928:
3925:
3923:
3920:
3918:
3915:
3913:
3910:
3908:
3905:
3903:
3902:Louis Pasteur
3900:
3898:
3897:Edward Jenner
3895:
3894:
3892:
3886:
3874:
3871:
3869:
3868:DTwP-HepB-Hib
3866:
3864:
3863:DTaP-IPV-HepB
3861:
3859:
3856:
3855:
3854:combination:
3853:
3851:
3848:
3846:
3843:
3841:
3838:
3836:
3833:
3829:
3826:
3822:
3819:
3817:
3814:
3813:
3812:
3809:
3807:
3804:
3802:
3799:
3797:
3794:
3793:
3792:
3789:
3787:
3784:
3783:
3781:
3777:
3769:
3766:
3764:
3761:
3760:
3758:
3757:
3755:
3753:
3752:Helminthiasis
3749:
3741:
3738:
3737:
3735:
3731:
3728:
3727:
3726:
3723:
3722:
3720:
3716:
3708:
3705:
3703:
3700:
3698:
3695:
3693:
3690:
3688:
3685:
3683:
3680:
3678:
3675:
3674:
3672:
3668:
3665:
3663:
3660:
3658:
3655:
3654:
3653:combination:
3652:
3650:
3647:
3643:
3640:
3638:
3635:
3634:
3632:
3630:
3627:
3625:
3622:
3620:
3617:
3613:
3610:
3608:
3605:
3603:
3600:
3598:
3595:
3593:
3590:
3588:
3585:
3583:
3580:
3578:
3575:
3573:
3570:
3568:
3565:
3563:
3560:
3558:
3555:
3553:
3550:
3548:
3545:
3543:
3540:
3539:
3538:
3535:
3533:
3530:
3528:
3525:
3523:
3520:
3516:
3513:
3511:
3508:
3507:
3506:
3503:
3501:
3498:
3496:
3493:
3491:
3488:
3486:
3483:
3479:
3476:
3474:
3471:
3470:
3469:
3466:
3464:
3461:
3459:
3456:
3454:
3451:
3449:
3446:
3442:
3439:
3437:
3434:
3431:
3427:
3424:
3423:
3422:
3419:
3415:
3412:
3411:
3410:
3407:
3405:
3402:
3400:
3397:
3396:
3394:
3390:
3382:
3379:
3377:
3374:
3372:
3369:
3368:
3366:
3362:
3359:
3357:
3356:DPT/DTwP/DTaP
3354:
3353:
3352:combination:
3351:
3349:
3346:
3342:
3339:
3337:
3334:
3333:
3332:
3329:
3325:
3322:
3321:
3320:
3317:
3315:
3312:
3310:
3307:
3303:
3300:
3298:
3295:
3294:
3293:
3290:
3288:
3285:
3283:
3280:
3276:
3273:
3271:
3268:
3267:
3266:
3265:Meningococcus
3263:
3261:
3258:
3256:
3255:Leptospirosis
3253:
3251:
3248:
3246:
3243:
3241:
3238:
3236:
3233:
3231:
3228:
3227:
3225:
3221:
3218:
3214:
3206:
3203:
3201:
3198:
3196:
3193:
3191:
3190:Vaccine court
3188:
3186:
3183:
3182:
3180:
3176:
3173:
3171:
3168:
3166:
3163:
3161:
3158:
3156:
3153:
3151:
3148:
3146:
3145:GAVI Alliance
3143:
3142:
3140:
3139:
3137:
3133:
3127:
3124:
3122:
3119:
3117:
3113:
3110:
3108:
3104:
3100:
3096:
3093:
3089:
3086:
3084:
3081:
3080:
3078:
3076:
3073:
3071:
3068:
3067:
3065:
3061:
3055:
3052:
3050:
3047:
3045:
3042:
3040:
3037:
3033:
3030:
3029:
3028:
3025:
3023:
3020:
3019:
3017:
3013:
3008:
3004:
3000:
2996:
2992:
2988:
2984:
2977:
2972:
2970:
2965:
2963:
2958:
2957:
2954:
2947:
2943:
2940:
2936:
2934:
2928:
2924:
2923:
2903:
2902:Fierce Pharma
2899:
2892:
2877:
2873:
2867:
2852:
2848:
2842:
2826:
2825:Bloomberg.com
2822:
2816:
2801:
2797:
2791:
2775:
2771:
2765:
2749:
2747:
2742:
2736:
2728:
2724:
2719:
2714:
2710:
2706:
2702:
2698:
2694:
2687:
2668:
2661:
2654:
2638:
2634:
2628:
2612:
2608:
2602:
2586:
2582:
2576:
2560:
2556:
2550:
2542:
2538:
2533:
2528:
2523:
2518:
2514:
2510:
2506:
2499:
2497:
2495:
2493:
2484:
2480:
2475:
2470:
2466:
2462:
2458:
2454:
2450:
2443:
2435:
2431:
2427:
2423:
2418:
2413:
2409:
2405:
2401:
2394:
2378:
2372:
2357:
2356:Fierce Pharma
2353:
2346:
2344:
2327:
2323:
2317:
2315:
2313:
2295:
2291:
2289:
2284:
2278:
2276:
2274:
2272:
2255:
2253:
2248:
2242:
2226:
2219:
2211:
2207:
2203:
2199:
2194:
2189:
2185:
2181:
2177:
2170:
2154:
2147:
2139:
2135:
2130:
2125:
2121:
2117:
2113:
2109:
2105:
2098:
2096:
2094:
2085:
2081:
2076:
2071:
2067:
2063:
2059:
2055:
2051:
2044:
2028:
2024:
2017:
2009:
2005:
2000:
1995:
1991:
1987:
1983:
1976:
1960:
1956:
1952:
1946:
1938:
1934:
1930:
1926:
1921:
1916:
1912:
1908:
1904:
1897:
1889:
1885:
1881:
1877:
1873:
1869:
1865:
1861:
1853:
1838:
1834:
1827:
1825:
1809:
1807:
1802:
1796:
1780:
1776:
1770:
1768:
1766:
1756:
1751:
1747:
1743:
1737:
1728:
1723:
1719:
1715:
1709:
1702:
1701:public domain
1683:
1679:
1677:
1671:
1665:
1657:
1651:
1649:
1632:
1625:
1623:
1607:
1606:
1601:
1594:
1592:
1575:
1571:
1565:
1549:
1545:
1539:
1523:
1519:
1513:
1505:
1501:
1497:
1495:9780128000984
1491:
1487:
1483:
1479:
1475:
1468:
1466:
1457:
1453:
1448:
1443:
1439:
1435:
1431:
1427:
1423:
1416:
1401:
1400:Fierce Pharma
1397:
1390:
1374:
1368:
1366:
1358:
1357:public domain
1339:
1335:
1333:
1327:
1321:
1319:
1317:
1315:
1313:
1311:
1309:
1307:
1305:
1303:
1301:
1284:
1278:
1276:
1260:
1256:
1249:
1247:
1238:
1234:
1230:
1226:
1221:
1216:
1212:
1208:
1204:
1200:
1193:
1184:
1179:
1175:
1171:
1167:
1161:
1159:
1157:
1148:
1144:
1140:
1136:
1132:
1128:
1121:
1112:
1107:
1103:
1099:
1095:
1089:
1081:
1077:
1072:
1067:
1063:
1059:
1055:
1051:
1047:
1040:
1038:
1036:
1019:
1015:
1009:
1007:
1005:
1003:
1001:
999:
982:
980:
975:
974:"Qdenga EPAR"
969:
967:
965:
948:
944:
942:
937:
931:
929:
912:
908:
902:
900:
898:
881:
877:
871:
855:
851:
845:
829:
825:
819:
803:
799:
793:
778:. 26 May 2022
777:
773:
767:
763:
755:
753:
749:
737:Controversies
734:
722:
719:
717:
713:
709:
705:
699:
694:
689:
687:
682:
680:
676:
661:
659:
656:In 2011, the
649:
647:
643:
634:
632:
628:
618:
615:
613:
609:
605:
600:
598:
595:, Vabiotech,
594:
590:
586:
581:
579:
574:
572:
557:
553:
549:
547:
542:
538:
534:
531:
527:
518:
509:
506:
501:
497:
493:
491:
486:
484:
480:
476:
470:
468:
462:
460:
456:
451:
448:
445:
441:
436:
431:
427:
425:
421:
417:
413:
403:
401:
396:
394:
389:
385:
381:
373:
371:
367:
363:
359:
354:
352:
351:a controversy
348:
344:
339:
337:
333:
329:
325:
321:
317:
305:
304:
302:
300:
296:
289:
285:
284:
282:
280:
276:
269:
265:
264:
262:
260:
256:
251:
244:
242: Rx-only
235:
226:
223:
213:
204:
201:
191:
190:
188:
186:
182:
177:
169:
164:
161:
160:
158:
156:
152:
149:
146:
144:
138:
131:
126:
117:
116:
114:
112:
108:
104:
100:
98:
94:
90:
86:
82:
78:
76:
72:
69:Clinical data
67:
64:
61:
59:
55:
52:
49:
45:
42:
38:
30:
19:
4131:Dengue fever
4024:Epidemiology
4000:
3972:
3858:DTaP-IPV/Hib
3681:
3649:Yellow fever
3562:EpiVacCorona
3319:Tuberculosis
3292:Pneumococcal
3260:Lyme disease
3088:Heterologous
2987:Immunization
2930:
2905:. Retrieved
2901:
2891:
2879:. Retrieved
2875:
2866:
2854:. Retrieved
2850:
2841:
2829:. Retrieved
2824:
2815:
2803:. Retrieved
2799:
2790:
2778:. Retrieved
2773:
2764:
2752:. Retrieved
2744:
2735:
2700:
2696:
2686:
2674:. Retrieved
2667:the original
2653:
2641:. Retrieved
2637:the original
2627:
2615:. Retrieved
2610:
2601:
2589:. Retrieved
2584:
2575:
2563:. Retrieved
2558:
2549:
2512:
2508:
2456:
2452:
2442:
2407:
2403:
2393:
2381:. Retrieved
2371:
2359:. Retrieved
2355:
2330:. Retrieved
2325:
2298:. Retrieved
2294:the original
2286:
2258:. Retrieved
2250:
2241:
2229:. Retrieved
2218:
2183:
2179:
2169:
2157:. Retrieved
2146:
2111:
2107:
2057:
2053:
2043:
2031:. Retrieved
2027:the original
2016:
1989:
1985:
1975:
1963:. Retrieved
1959:the original
1954:
1945:
1910:
1906:
1896:
1863:
1859:
1852:
1840:. Retrieved
1836:
1811:. Retrieved
1804:
1795:
1783:. Retrieved
1778:
1755:10665/345533
1745:
1736:
1727:10665/325771
1717:
1708:
1686:. Retrieved
1673:
1664:
1635:. Retrieved
1609:. Retrieved
1603:
1580:20 September
1578:. Retrieved
1573:
1564:
1554:20 September
1552:. Retrieved
1547:
1538:
1526:. Retrieved
1521:
1512:
1477:
1473:
1429:
1425:
1415:
1403:. Retrieved
1399:
1389:
1377:. Retrieved
1342:. Retrieved
1329:
1287:. Retrieved
1262:. Retrieved
1258:
1205:(4): e2101.
1202:
1198:
1192:
1183:10665/274316
1173:
1169:
1130:
1127:J Travel Med
1126:
1120:
1111:10665/374327
1101:
1097:
1088:
1053:
1049:
1022:. Retrieved
1017:
985:. Retrieved
977:
951:. Retrieved
939:
915:. Retrieved
910:
884:. Retrieved
879:
870:
858:. Retrieved
853:
844:
832:. Retrieved
827:
818:
806:. Retrieved
801:
792:
780:. Retrieved
775:
766:
745:
728:
720:
690:
683:
672:
669:Legal status
655:
652:DNA vaccines
640:
624:
616:
601:
582:
575:
568:
554:
550:
537:dengue virus
523:
502:
498:
494:
487:
471:
463:
452:
432:
428:
414:, is a live
409:
397:
390:
386:
382:
379:
355:
340:
335:
331:
324:dengue fever
315:
314:
268:1704605-80-0
185:Legal status
179:Legal status
148:Subcutaneous
111:License data
58:Vaccine type
51:Dengue fever
29:
4060:from market
3956:Controversy
3890:researchers
3806:Hepatitis B
3692:Hepatitis C
3637:Chicken pox
3463:Hepatitis E
3458:Hepatitis B
3453:Hepatitis A
3404:Chikungunya
3381:Shigellosis
3235:Brucellosis
3121:Therapeutic
3075:Inactivated
3015:Development
3003:Inoculation
2995:Vaccination
2780:10 February
2611:India Times
2515:: 6803098.
2231:11 November
2159:18 February
2033:10 December
1842:13 December
1670:"Dengvaxia"
1480:: 315–372.
1405:25 November
1379:25 November
1344:14 November
1264:14 December
1024:14 November
987:28 December
742:Philippines
696: [
530:recombinant
455:anaphylaxis
362:inactivated
253:Identifiers
84:Other names
75:Trade names
4125:Categories
3991:Thiomersal
3937:Paul Offit
3912:Jonas Salk
3888:Inventors/
3759:research:
3736:research:
3673:research:
3602:Skycovione
3592:Sanofi–GSK
3537:SARS-CoV-2
3448:Hantavirus
3414:rVSV-ZEBOV
3399:Adenovirus
3367:research:
3245:Diphtheria
3083:Attenuated
2876:MercoPress
2851:MercoPress
2831:9 February
2754:14 October
2617:26 October
2591:26 October
2565:26 October
2300:14 October
2260:14 October
1785:2 December
1688:6 December
1637:17 October
1432:(1): 3–9.
1133:(7): 1–3.
953:6 December
854:CNN Brazil
758:References
646:Drosophila
565:TV-003/005
483:serostatus
444:virologist
416:attenuated
347:serostatus
299:ChemSpider
259:CAS Number
63:Attenuated
4070:Phase III
4058:Withdrawn
3986:Pox party
3796:ALVAC-CEA
3718:Protozoan
3607:Sputnik V
3557:CoronaVac
3527:Rotavirus
3430:Pandemrix
3282:Pertussis
3223:Bacterial
3107:Synthetic
3070:Conjugate
3022:Adjuvants
2999:Infection
2434:206690615
2332:3 October
2210:207952783
2155:. Reuters
1813:5 October
1611:13 August
1528:13 August
1237:211536962
1018:Drugs.com
725:Economics
712:Argentina
621:TDENV PIV
332:Dengvaxia
328:serotypes
141:Routes of
130:Dengvaxia
103:Monograph
97:Drugs.com
4136:Vaccines
4103:Medicine
3828:Prostvac
3821:Gardasil
3816:Cervarix
3763:Hookworm
3642:Shingles
3624:Smallpox
3542:Corbevax
3478:Gardasil
3473:Cervarix
3216:Vaccines
3170:Schedule
3141:Global:
3049:Timeline
2991:Vaccines
2727:30427741
2541:27525287
2483:26559731
2426:27089205
2202:31693803
2138:25989449
2084:21777638
2008:26214039
1929:25365753
1888:42841451
1880:25018116
1744:(2021).
1716:(2019).
1682:Archived
1504:24373316
1456:24757522
1338:Archived
1289:28 March
1229:32101634
1147:37847608
1080:23984962
947:Archived
911:DailyMed
834:31 March
533:chimeric
505:efficacy
279:DrugBank
155:ATC code
125:DailyMed
4115:Viruses
4089:Portals
4017:Related
3963:General
3725:Malaria
3612:Valneva
3577:Novavax
3572:Moderna
3567:Janssen
3552:CanSino
3532:Rubella
3490:Measles
3361:Td/Tdap
3331:Typhoid
3314:Tetanus
3309:Q fever
3240:Cholera
3230:Anthrax
3099:Peptide
3063:Classes
3044:Storage
2907:14 July
2805:3 March
2718:6773383
2676:31 July
2643:31 July
2585:Medigen
2532:4971387
2474:4956407
2383:30 July
2361:14 July
2326:Reuters
2129:4470297
2108:Vaccine
2075:4592106
2054:Vaccine
1965:13 July
1937:2839926
1837:Reuters
1605:Reuters
1447:3991153
1071:3773977
886:9 April
860:29 June
808:9 April
782:9 April
731:US$ 207
528:, is a
376:History
320:vaccine
288:DB15521
171:)
165: (
163:J07BX04
127::
87:CYD-TDV
4053:WHO-EM
3973:Lancet
3850:TA-NIC
3835:NicVAX
3682:Dengue
3522:Rabies
3348:Typhus
3287:Plague
3165:Policy
3126:Toxoid
3054:Trials
2948:(MeSH)
2881:3 June
2856:3 June
2774:Takeda
2725:
2715:
2539:
2529:
2481:
2471:
2432:
2424:
2208:
2200:
2136:
2126:
2082:
2072:
2006:
1935:
1927:
1886:
1878:
1860:Lancet
1779:CIDRAP
1574:CIDRAP
1502:
1492:
1454:
1444:
1235:
1227:
1145:
1078:
1068:
917:17 May
704:Qdenga
526:Takeda
336:Qdenga
220:
198:
123:
47:Target
3981:NCVIA
3845:TA-CD
3779:Other
3730:RTS,S
3510:Sabin
3505:Polio
3500:Mumps
3409:Ebola
3392:Viral
3341:ViCPS
3336:Ty21a
3270:MeNZB
3200:VAERS
3150:NITAG
3079:Live
2935:(CDC)
2931:U.S.
2748:(EMA)
2670:(PDF)
2663:(PDF)
2559:Merck
2430:S2CID
2290:(EMA)
2254:(EMA)
2206:S2CID
1933:S2CID
1884:S2CID
1808:(WHO)
1678:(FDA)
1674:U.S.
1633:. CNN
1334:(FDA)
1330:U.S.
1233:S2CID
981:(EMA)
943:(EMA)
880:(emc)
700:]
642:Merck
597:Merck
571:NIAID
318:is a
3707:Zika
3667:MMRV
3515:Salk
3495:Mpox
3441:LAIV
3436:H5N1
3426:H1N1
3302:PPSV
3185:ACIP
3181:US:
3155:SAGE
3116:mRNA
3032:list
2909:2023
2883:2024
2858:2024
2833:2023
2807:2023
2782:2023
2756:2022
2723:PMID
2678:2015
2645:2015
2619:2021
2593:2021
2567:2021
2537:PMID
2513:2016
2479:PMID
2422:PMID
2385:2015
2363:2023
2334:2023
2302:2022
2262:2022
2233:2019
2198:PMID
2161:2018
2134:PMID
2080:PMID
2035:2015
2004:PMID
1967:2014
1925:PMID
1876:PMID
1844:2017
1815:2021
1787:2017
1690:2019
1639:2016
1613:2017
1582:2020
1556:2020
1530:2017
1522:STAT
1500:PMID
1490:ISBN
1452:PMID
1407:2022
1381:2022
1346:2019
1291:2021
1266:2017
1259:STAT
1225:PMID
1143:PMID
1076:PMID
1026:2019
989:2022
955:2019
919:2020
888:2023
862:2023
836:2024
810:2023
784:2023
746:The
637:V180
576:The
488:The
368:and
334:and
306:none
93:AHFS
3968:MMR
3811:HPV
3801:BCG
3702:HIV
3662:MMR
3468:HPV
3421:Flu
3324:BCG
3297:PCV
3250:Hib
3205:VSD
3112:DNA
3007:J07
2713:PMC
2705:doi
2527:PMC
2517:doi
2469:PMC
2461:doi
2412:doi
2188:doi
2184:381
2124:PMC
2116:doi
2070:PMC
2062:doi
1994:doi
1990:373
1915:doi
1911:372
1868:doi
1864:384
1750:hdl
1722:hdl
1482:doi
1442:PMC
1434:doi
1215:hdl
1207:doi
1178:hdl
1135:doi
1106:hdl
1066:PMC
1058:doi
608:NIH
366:DNA
222:POM
168:WHO
4127::
4066::
3114:/
3105:/
3101:/
3097:/
3001:,
2997:,
2993:,
2989::
2985:/
2929:.
2900:.
2874:.
2849:.
2823:.
2798:.
2772:.
2743:.
2721:.
2711:.
2701:15
2699:.
2695:.
2609:.
2583:.
2557:.
2535:.
2525:.
2511:.
2507:.
2491:^
2477:.
2467:.
2457:15
2455:.
2451:.
2428:.
2420:.
2406:.
2402:.
2354:.
2342:^
2324:.
2311:^
2285:.
2270:^
2249:.
2204:.
2196:.
2182:.
2178:.
2132:.
2122:.
2112:33
2110:.
2106:.
2092:^
2078:.
2068:.
2058:29
2056:.
2052:.
2002:.
1988:.
1984:.
1953:.
1931:.
1923:.
1909:.
1905:.
1882:.
1874:.
1862:.
1835:.
1823:^
1803:.
1777:.
1764:^
1672:.
1647:^
1621:^
1602:.
1590:^
1572:.
1546:.
1520:.
1498:.
1488:.
1478:88
1476:.
1464:^
1450:.
1440:.
1428:.
1424:.
1398:.
1364:^
1328:.
1299:^
1274:^
1257:.
1245:^
1231:.
1223:.
1213:.
1203:30
1201:.
1174:93
1172:.
1155:^
1141:.
1131:30
1129:.
1102:98
1100:.
1074:.
1064:.
1054:12
1052:.
1048:.
1034:^
1016:.
997:^
976:.
963:^
938:.
927:^
909:.
896:^
878:.
826:.
800:.
774:.
718:.
698:es
610:.
591:,
587:,
485:.
469:.
372:.
364:,
360:,
338:.
238:EU
229:US
216:UK
207:BR
200:S4
194:AU
120:US
4091::
3977:)
3970:(
3432:)
3428:(
3009:)
3005:(
2975:e
2968:t
2961:v
2911:.
2885:.
2860:.
2835:.
2809:.
2784:.
2758:.
2729:.
2707::
2680:.
2647:.
2621:.
2595:.
2569:.
2543:.
2519::
2485:.
2463::
2436:.
2414::
2408:8
2387:.
2365:.
2336:.
2304:.
2264:.
2235:.
2212:.
2190::
2163:.
2140:.
2118::
2086:.
2064::
2037:.
2010:.
1996::
1969:.
1939:.
1917::
1890:.
1870::
1846:.
1817:.
1789:.
1752::
1724::
1703:.
1692:.
1641:.
1615:.
1584:.
1558:.
1532:.
1506:.
1484::
1458:.
1436::
1430:2
1409:.
1383:.
1359:.
1348:.
1293:.
1268:.
1239:.
1217::
1209::
1186:.
1180::
1149:.
1137::
1114:.
1108::
1082:.
1060::
1028:.
991:.
957:.
921:.
890:.
864:.
838:.
812:.
786:.
240::
231::
218::
209::
196::
95:/
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.